Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC.

 (MRK)

55
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Sector
Healthcare
Biotechnology / Pharmaceuticals
 Biotechnology / Pharmaceuticals
  Pharmaceuticals - Diversified
Logo
Logo Merck & Co., Inc.
Business Summary
Merck and Company specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (67.1%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (10%);
- other (22.9%).
Net sales break down geographically as follows: the United States (43.1%), Europe-Middle East-Africa (27.5%), Japan (10.8%) and other (18.6%).
Surperformance© rating of Merck & Co., Inc.
Overall rating In sector In country
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals - Diversified
CountryTrading RatingInvestor Rating
JOHNSON & JOHNSONUSA
ROCHE HOLDING LTD.Switzerland
PFIZER INC.USA
NOVARTIS AGSwitzerland
SANOFIFrance
MERCK & CO., INC.USA
GLAXOSMITHKLINE PLCUnited Kingdom
BAYER AGGermany
NOVO NORDISK A/SDenmark
BRISTOL MYERS SQUIBB CO.USA
ELI LILLY & CO.USA
ABBOTT LABORATORIESUSA
TEVA PHARMACEUTICAL INDUSTRIES LIMITEDISRAEL
ALEXION PHARMACEUTICALS, INC.USA
SHIRE PLCUnited Kingdom
ACTAVIS INCUSA
DAIICHI SANKYO COMPANY, LIMITEDJapan
CHUGAI PHARMACEUTICAL CO., LTD.Japan
MYLAN INC.USA
UCBBelgium
BIOMARIN PHARMACEUTICAL INC.USA
TASLY PHARMACEUTICAL GROUP CO LTDCHINA
TAISHO PHARMACEUTICAL HOLDINGS CO LTDJapan
HISAMITSU PHARMACEUTICAL CO., INC.Japan
WARNER CHILCOTT PLCUSA
Sector Pharmaceuticals - Diversified
Data source :
© 2013 Thomson Reuters
Ratings :
© 2013 Surperformance
Shareholders
- Capital World 6,40%
- BlackRock 5,75%
Advertisement
Managers
- General Secretary :
    Celia A. Colbert
- Chief Financial Officer :
    Peter N. Kellogg
- Chairman and Chief Executive Officer :
    Kenneth C. Frazier
Company contact information
One Merk Drive
PO Box 100
NJ 08889-0100 Whitehouse Station, New Jersey
USA

Phone : +1 908 423 1000
Fax : +1 908 735 1253
Internet : http://www.merck.com
Markets and indexes
- NYSE Euronext Paris
- Eurolist hors zone Euro
- CAC International 25 / DJIA, SP100, SP500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50
Stock Exchange Codes
- ISIN Code :  US58933Y1055
- Bloomberg Code :  
- Reuters Code :  MRK.PA
- Datastream Code :  F:MERC
Financial data source :
© 2013 Cofisem
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.